Gossamer Bio, Inc.

Overview

Compare with Lexicon Pharmaceuticals, Contineum Therapeutics, Inc. or Semnur Pharmaceuticals, Inc., or pick any stock.

• TickerGOSS on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersSan Diego, United States²
• Incorporated inDE³
• Business address3115 Merryfield Row, Suite 120, San Diego, Ca 92121³
• Filer categoryNon-accelerated filer, Smaller reporting company³
• Legal formCorporation²
• LEI549300ZOC0N2W6PSFR58²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 5861073²

See how the biggest companies compare on our leaderboards

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this annual report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this annual report and are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, “Risk Factors.” The events and circumstances reflected in our forward-looking statements…⁴ From its latest annual report

Leadership

Who has led Gossamer Bio, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerFaheem Hasnain Mar 1, 2021 to now¹⁴
• Chief executive officerSheila Gujrathi Feb 7, 2019 to Feb 19, 2020¹⁵
• ChairFaheem Hasnain Feb 7, 2019 to Mar 26, 2019¹⁶
• PresidentFaheem Hasnain Mar 1, 2021 to now¹⁴
• PresidentSheila Gujrathi Feb 7, 2019 to Feb 19, 2020¹⁵
• Chief financial officerBryan Giraudo Feb 7, 2019 to now¹⁷
• Chief operating officerBryan Giraudo Sep 20, 2021 to now¹⁸

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerChristian D. Waage named Jul 18, 2022 to Sep 4, 2026³⁷
• Executive OfficerRobert D. Smith named Sep 4, 2026³⁷
• Executive OfficerLaura Carter, Ph.D. named Jul 18, 2022³⁸

Timeline

1. Mar 1, 2021New chief executive Faheem Hasnain becomes CEO¹⁴
2. Feb 7, 2019New chief executive Sheila Gujrathi becomes CEO¹⁵

Filings

309 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 145 insider forms, 42 large holders, 3 private raises, 38 other. The latest 20:

1. Oct 8, 2026SCHEDULE 13D/A EDGAR
2. Sep 28, 20268-K EDGAR
3. Sep 28, 2026SCHEDULE 13D/A EDGAR
4. Sep 25, 20264 EDGAR
5. Sep 25, 20264 EDGAR
6. Sep 25, 20264 EDGAR
7. Sep 25, 20264 EDGAR
8. Sep 25, 20264 EDGAR
9. Sep 25, 20264 EDGAR
10. Sep 25, 20264 EDGAR
11. Sep 23, 20268-K EDGAR
12. Sep 22, 20263 EDGAR
13. Sep 16, 2026DEF 14A EDGAR
14. Sep 16, 20268-K EDGAR
15. Sep 11, 20268-K EDGAR
16. Sep 9, 20268-K EDGAR
17. Sep 4, 2026D EDGAR
18. Sep 3, 2026PRE 14A EDGAR
19. Sep 3, 20268-K EDGAR
20. Aug 26, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 16 buys and 26 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• D. E. SHAW & CO, L.P.SCHEDULE 13D/A, 6 filings Jun 11, 2026 to Oct 8, 2026³⁹
• BlackRockSCHEDULE 13G/A, 2 filings Jan 21, 2026 to Jul 29, 2026⁴⁰
• Opaleye Management Inc.SCHEDULE 13G, 1 filing Jul 29, 2026⁴¹
• 683 Capital Management, LLCSCHEDULE 13G, 3 filings Mar 2, 2026 to Jun 11, 2026⁴²
• DeepCurrents Investment Group LLCSCHEDULE 13G, 1 filing Jun 11, 2026⁴³
• Context Capital Management, LLCSCHEDULE 13G, 1 filing Jun 9, 2026⁴⁴
• Octagon Capital Advisors LPSCHEDULE 13G/A, 3 filings Feb 5, 2025 to May 14, 2026⁴⁵
• VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 10, 2022 to Mar 27, 2026⁴⁶
• Growth Equity Opportunities 18 VGE, LLCSCHEDULE 13D/A, 2 filings Jul 28, 2023 to Feb 24, 2026⁴⁷
• Invus Global Management, LLCSCHEDULE 13G/A, 3 filings Aug 2, 2024 to Feb 12, 2025⁴⁸
• FMR LLCSC 13G/A, 2 filings Feb 9, 2024 to Nov 12, 2024⁴⁹
• HILLHOUSE INVESTMENT MANAGEMENT, LTD.SC 13G/A, 1 filing Feb 14, 2024⁵⁰
• ARCH Venture Fund IX, L.P.SC 13G/A, 1 filing Feb 9, 2024⁵¹
• Artal International S.C.A.SC 13G, 1 filing Jan 11, 2024⁵²
• MILLENNIUM MANAGEMENT LLCSC 13G/A, 3 filings Dec 20, 2022 to Jan 11, 2024⁵³
• State Street CorporationSC 13G/A, 2 filings Jan 10, 2023 to May 10, 2023⁵⁴
• HHLR ADVISORS, LTD.SC 13G/A, 1 filing Feb 14, 2023⁵⁵

Money raised

Private offerings the company reported to the SEC on Form D.

1. Aug 20, 2026Raised $25 million in a private offering of securities Form D: $150 million offered in all Form D
2. Jul 24, 2023Raised $212.1 million in a private offering of equity Form D: 70 investors so far Form D
3. Jul 15, 2022Raised $120 million in a private offering of equity Form D: 23 investors so far Form D